Use of a mammalian gonadotropin-releasing hormone (GnRH) agonist to characterize pituitary GnRH receptors in white sturgeon (Acipenser transmontanusRichardson)

2012 ◽  
Vol 28 (5) ◽  
pp. 687-691 ◽  
Author(s):  
B. Mojazi Amiri ◽  
T. E. Adams ◽  
S. I. Doroshov ◽  
M. Paktinat
1995 ◽  
Vol 132 (2) ◽  
pp. 163-170 ◽  
Author(s):  
Anne Marie Brandi ◽  
Gaëlle Barrande ◽  
Najiba Lahlou ◽  
Michèle Crumeyrolle ◽  
Myriam Berthet ◽  
...  

Brandi AM, Barrande G, Lahlou N, Crumeyrolle M, Berthet M, Leblanc P, Peillon F, Li JY. Stimulatory effect of gonadotropin-releasing hormone (GnRH) on in vitro prolactin secretion and presence of GnRH specific receptors in a subset of human prolactinomas. Eur J Endocrinol 1995;132:163–70. ISSN 0804–4643 The purpose of this study was to determine whether gonadotropin-releasing hormone (GnRH) may exert a direct action on human prolactinomas. On a series of 17 adenomas, we studied the effect of GnRH on the in vitro prolactin (PRL) secretion of dispersed and perifused cells of 10 cases and the [125I]GnRH agonist binding on frozen sections of three out of the adenomas studied in perifusion and on the membrane preparations of seven other cases. Two 20-min pulses of GnRH (10−7 mol/l) stimulated the in vitro PRL secretion of three adenomas out of 10 (increase of 200, 444 and 205%, respectively, above basal levels). The GnRH receptors of three adenomas bound GnRH agonist (Des-Gly10-(d-Ala6)-GnRH ethylamide). The binding was specific, with a high affinity (Kd = 0.60, 0.48 and 0.40 nmol/l) similar to that of two human anterior pituitaries obtained post-mortem (Kd = 0.70 and 0.40 nmol/l). Indirect immunoperoxidase revealed that the majority of the cells (60–90%) in all the adenomas studied contained immunoreactive PRL. Four of them also contained cells immunoreactive to the α-subunit of the glycoprotein hormones. In none of the prolactinomas were cells immunoreactive to antiserum of anti-β-luteinizing hormone, anti-β-follicle-stimulating hormone or anti-β-thyrotropin. All the prolactinomas that were responsive to GnRH in perifusion experiments and/or bound specifically to [125I]GnRH agonist were also immunoreactive for α-subunit. These results show that GnRH, via GnRH specific receptors, exerts a stimulation on in vitro PRL secretion in a subset of prolactinomas characterized by the presence of α-subunit. Anne Marie Brandi, Unité INSERM 223, Faculté de Médecine Pitié-Salpêtrière, 105 Boulevard de l'Hôpital, 75013 Paris, France


1986 ◽  
Vol 20 (10) ◽  
pp. 746-751 ◽  
Author(s):  
Norbert J. Wojciechowski ◽  
Charles A. Carter ◽  
Vasilios A. Skoutakis ◽  
David T. Bess ◽  
William J. Falbe ◽  
...  

Leuprolide is the first member of the class of gonadotropin-releasing hormone (GnRH) agonist analog to be released in the U.S. The pharmacology of leuprolide is complex and not yet completely defined. This agonist analog is more potent than natural GnRH and appears to be capable of occupying pituitary GnRH receptors. This results in a “down regulation” of the receptors' activity and gonadotropin release, ultimately decreasing serum testosterone levels to those seen following castration. Leuprolide has been found effective in the palliative treatment of advanced cases of prostatic cancer and is not associated with the cardiovascular and thromboembolic toxicity seen with conventional diethylstilbestrol therapy. Leuprolide is administered by daily subcutaneous injections and has been generally well tolerated. The most common adverse effects are hot flashes and a possible flare-up of prostatic carcinoma symptoms on initial dosing. As clinical experience grows in the use of GnRH agonist analog, GnRH will assume a greater role in the treatment of metastatic prostatic cancer.


2007 ◽  
Vol 88 ◽  
pp. S126
Author(s):  
E.B. Johnston-MacAnanny ◽  
C.A. Benadiva ◽  
L.J. Siano ◽  
J.C. Nulsen ◽  
D.B. Maier ◽  
...  

1981 ◽  
Vol 36 (11) ◽  
pp. 633-634
Author(s):  
DAVID R. PIEPER ◽  
JOANN S. RICHARDS ◽  
JOHN C. MARSHALL

Sign in / Sign up

Export Citation Format

Share Document